Distigmine

證據等級: L5

預測適應症: 10 個

Distigmine: From Detrusor Underactivity to Myasthenia Gravis with Thymus Hyperplasia

One-Sentence Summary

Distigmine (DB13694) is an acetylcholinesterase inhibitor (AChEI) used in Japan for detrusor underactivity — a bladder condition characterised by impaired detrusor muscle contraction. The TxGNN model predicts it may be effective for Myasthenia Gravis with Thymus Hyperplasia (TxGNN score: 99.9984%), which is mechanistically plausible given that AChEIs are already the cornerstone of MG therapy. However, no clinical trials or literature currently exist specifically linking Distigmine to this MG subtype, leaving the evidence at preclinical/mechanistic level only.

Quick Overview

Item	Content
Original Indication	Detrusor underactivity (urinary retention)
Predicted New Indication	Myasthenia Gravis with Thymus Hyperplasia
TxGNN Prediction Score	99.9984%
Evidence Level	L4
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Distigmine is a long-acting carbamate-type acetylcholinesterase inhibitor. By inhibiting AChE, it prevents the breakdown of acetylcholine (ACh) at the neuromuscular junction (NMJ), resulting in a sustained elevation of ACh concentration. A 2010 receptor binding study (PMID 20410601) further confirmed that Distigmine has direct binding activity at both muscarinic and nicotinic receptors — a dual-action profile that distinguishes it from simpler AChEIs.

Myasthenia gravis with thymus hyperplasia is the most common subtype of MG, characterised by autoantibodies against acetylcholine receptors (AChR) that reduce the number of functional AChRs at the NMJ. Elevating ACh availability — exactly what AChEIs do — compensates for this receptor loss and is the rationale behind pyridostigmine being the established first-line treatment for MG worldwide. Since Distigmine shares the same core mechanism and reportedly has a longer duration of action than pyridostigmine, the TxGNN model's prediction is pharmacologically coherent.

Distigmine's longer half-life is a theoretical advantage in MG (less frequent dosing), but it also increases the risk of cholinergic crisis. The absence of any MG-specific clinical data for Distigmine means this mechanistic logic has not been clinically validated. For thymus hyperplasia-associated MG specifically, thymectomy and immunosuppression remain the primary disease-modifying approaches; AChEI would serve as symptomatic adjunct therapy.

Clinical Trial Evidence

Currently no related clinical trials registered for Distigmine in myasthenia gravis with thymus hyperplasia.

Literature Evidence

Currently no related literature available for Distigmine in myasthenia gravis with thymus hyperplasia.

Singapore Market Information

Distigmine has no registered products in Singapore. The drug is primarily available in Japan under local regulatory approval for detrusor underactivity.

Safety Considerations

Please refer to the package insert for safety information.

Note: Distigmine is an acetylcholinesterase inhibitor. As a class effect, clinicians should be aware of the risk of cholinergic excess (bradycardia, excessive secretions, muscle fasciculation, cholinergic crisis), which is particularly relevant at higher doses or in patients with impaired drug clearance. The long half-life of Distigmine compared to pyridostigmine may increase this risk. No drug interaction data or formal contraindication data were retrievable for this Evidence Pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic rationale for using Distigmine in myasthenia gravis with thymus hyperplasia is strong — it shares the same AChEI mechanism as the established standard-of-care drug pyridostigmine. However, the complete absence of clinical trials, MG-specific publications, and Singapore regulatory registration means there is no translational evidence chain to support proceeding toward clinical development or formulary evaluation at this time.

To proceed, the following is needed:

MOA verification: Retrieve full DrugBank pharmacology profile (mechanism, targets, ADME) to formally characterise Distigmine vs. pyridostigmine
Comparative pharmacokinetic data: Establish half-life, bioavailability, and dose equivalence versus pyridostigmine in humans
MG-specific case reports or observational data: Systematic search in Japanese literature (J-Stage, Ichushi) where Distigmine has regulatory approval and clinical use
Safety profile for MG patients: Package insert data from Japanese PMDA approval for detrusor underactivity; evaluate cholinergic crisis risk thresholds
Regulatory pathway assessment: Determine whether an off-label use pathway or new indication study would be required in Singapore given zero local registration
Subtype relevance analysis: Clarify whether thymus hyperplasia-associated MG patients respond differently to long-acting vs. short-acting AChEIs, to assess whether Distigmine's longer duration of action is a net benefit or risk in this specific subtype
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.